- Conditions
- Active Noninfectious Uveitis Affecting the Posterior Segment
- Interventions
- REGN7041
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Sacramento, California • Oak Park, Illinois • Nashville, Tennessee + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 1,616
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinitis Pigmentosa
- Interventions
- Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia
- Interventions
- Retinal fundus photography
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Retinitis Pigmentosa
- Interventions
- Transcorneal Electrical Stimulation using Okustim device
- Device
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 22 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Retinopathy of Prematurity (ROP)
- Interventions
- Not listed
- Lead sponsor
- Alaska Blind Child Discovery
- Other
- Eligibility
- Not listed
- Enrollment
- 7,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Anchorage, Alaska
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
- Interventions
- Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
- Other · Diagnostic Test · Genetic
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Aflibercept Injection
- Drug
- Lead sponsor
- Greater Houston Retina Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • Orlando, Florida • Winter Haven, Florida + 10 more
- Conditions
- Pain
- Interventions
- Intravitreal injection site
- Procedure
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Macular Degeneration
- Interventions
- Lucentis, Ranibizumab, Ranibizumab (Lucentis)
- Drug
- Lead sponsor
- The National Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Chevy Chase, Maryland • Towson, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Hilo, Hawaii
- Conditions
- CYSTOID MACULAR EDEMA
- Interventions
- Ranibizumab,, Triamcinolone acetonide
- Drug
- Lead sponsor
- Soll Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Macular Edema
- Interventions
- abicipar pegol, ranibizumab, sham procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Gilbert, Arizona • Abilene, Texas
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration (nAMD)
- Interventions
- EXG102-031
- Biological
- Lead sponsor
- Exegenesis Bio
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Reno, Nevada • Erie, Pennsylvania
- Conditions
- Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
- Interventions
- Not listed
- Lead sponsor
- Optovue
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Daly City, California • Petaluma, California • Walnut Creek, California
- Conditions
- Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
- Interventions
- i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
- Device
- Lead sponsor
- i-Lumen Scientific, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
- Conditions
- Low Vision
- Interventions
- Virtual bioptic magnification with large field of view, Full field magnification with small field of view
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 14 Years to 100 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Geographic Atrophy of the Macula
- Interventions
- GAL-101, Placebo
- Drug
- Lead sponsor
- Galimedix Therapeutics Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
- Conditions
- Retinal Disease, Glaucoma
- Interventions
- P200TE, Spectral OCT/SLO
- Device
- Lead sponsor
- Optos, PLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Age-related Macular Degeneration
- Interventions
- MT-0814, Placebo
- Drug
- Lead sponsor
- Senju Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 13
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Pasadena, California + 10 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-hRPGRco, Control
- Biological · Drug
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more
- Conditions
- Diabetic Retinopathy, Macular Degeneration
- Interventions
- intravitreal injection of infliximab
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
- Interventions
- Pozelimab, Cemdisiran, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 158
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 125 more
- Conditions
- Retinoblastoma
- Interventions
- Chemoplaque also referred to as Episcleral Topotecan
- Drug
- Lead sponsor
- Targeted Therapy Technologies, LLC
- Industry
- Eligibility
- Up to 8 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- New York, New York • Milwaukee, Wisconsin